SLDB
Price:
$4.18
Market Cap:
$167.01M
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new ...[Read more]
Industry
Biotechnology
IPO Date
2018-01-26
Stock Exchange
NASDAQ
Ticker
SLDB
According to Solid Biosciences Inc.’s latest financial reports and current stock price. The company's current ROE is -58.75%. This represents a change of 290.48% compared to the average of -15.04% of the last 4 quarters.
The mean historical ROE of Solid Biosciences Inc. over the last ten years is -32.34%. The current -58.75% ROE has changed 81.68% with respect to the historical average. Over the past ten years (40 quarters), SLDB's ROE was at its highest in in the December 2017 quarter at 24.45%. The ROE was at its lowest in in the September 2020 quarter at -95.57%.
Average
-32.34%
Median
-34.64%
Minimum
-144.47%
Maximum
87.95%
Discovering the peaks and valleys of Solid Biosciences Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 244.48%
Maximum Annual ROE = 87.95%
Minimum Annual Increase = -167.94%
Minimum Annual ROE = -144.47%
Year | ROE | Change |
---|---|---|
2023 | -75.91% | 145.28% |
2022 | -30.95% | -10.65% |
2021 | -34.64% | -49.23% |
2020 | -68.23% | -52.77% |
2019 | -144.47% | 141.78% |
2018 | -59.75% | -167.94% |
2017 | 87.95% | 244.48% |
2016 | 25.53% | 170.31% |
The current ROE of Solid Biosciences Inc. (SLDB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-47.17%
5-year avg
-70.84%
10-year avg
-32.34%
Solid Biosciences Inc.’s ROE is greater than Century Therapeutics, Inc. (-66.58%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Cullinan Oncology, Inc. (-26.54%), greater than TCR2 Therapeutics Inc. (-71.90%), greater than Revolution Medicines, Inc. (-33.67%), greater than Black Diamond Therapeutics, Inc. (-68.08%), greater than Atreca, Inc. (-199.88%), greater than Passage Bio, Inc. (-72.53%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.95%), greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than Molecular Partners AG (-39.16%), less than Stoke Therapeutics, Inc. (0%), greater than Monte Rosa Therapeutics, Inc. (-54.45%), greater than Cabaletta Bio, Inc. (-62.68%), greater than Larimar Therapeutics, Inc. (-50.10%), greater than Alector, Inc. (-35.87%), greater than null (-108.77%),
Company | ROE | Market cap |
---|---|---|
-66.58% | $87.15M | |
-26.83% | $2.80B | |
-42.45% | $273.18M | |
-55.92% | $637.04M | |
-26.54% | $714.45M | |
-71.90% | $58.11M | |
-33.67% | $8.09B | |
-68.08% | $123.92M | |
-199.88% | $3.57M | |
-72.53% | $40.24M | |
-184.40% | $42.01M | |
-47.95% | $193.98M | |
-24.20% | $76.07M | |
-39.16% | $195.74M | |
0% | $599.59M | |
-54.45% | $433.13M | |
-62.68% | $114.37M | |
-50.10% | $241.19M | |
-35.87% | $181.18M | |
-108.77% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Solid Biosciences Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Solid Biosciences Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Solid Biosciences Inc.'s ROE?
How is the ROE calculated for Solid Biosciences Inc. (SLDB)?
What is the highest ROE for Solid Biosciences Inc. (SLDB)?
What is the 3-year average ROE for Solid Biosciences Inc. (SLDB)?
What is the 5-year average ROE for Solid Biosciences Inc. (SLDB)?
How does the current ROE for Solid Biosciences Inc. (SLDB) compare to its historical average?